Directory
Xavier Matias-Guiu Guia

Xavier Matias-Guiu Guia

Degree: PhD

973 705 340
fjmatiasguiu.lleida.ics(ELIMINAR)@gencat.cat

ResearcherID: http://www.researcherid.com/rid/C-3039-2009

Publications

  • Aldecoa, I; Atares, B; Tarragona, J; Bernet, L; Sardon, JD; Pereda, T; Villar, C; Mendez, MC; Gonzalez-Obeso, E; Elorriaga, K; Alonso, GL; Zamora, J; Planell, N; Palacios, J; Castells, A; Matias-Guiu, X; Cuatrecasas, M

    Molecularly determined total tumour load in lymph nodes of stage I-II colon cancer patients correlates with high-risk factors. A multicentre prospective study

    VIRCHOWS ARCHIV 469 385-394. .

    [doi:10.1007/s00428-016-1990-1]

  • van der Putten, LJM; Visser, NCM; van de Vijver, K; Santacana, M; Bronsert, P; Bulten, J; Hirschfeld, M; Colas, E; Gil-Moreno, A; Garcia, A; Mancebo, G; Alameda, F; Trovik, J; Kopperud, RK; Huvila, J; Schrauwen, S; Koskas, M; Walker, F; Weinberger, V; Minar, L; Jandakova, E; Snijders, MPLM; van den Berg-van Erp, S; Matias-Guiu, X; Salvesen, HB; Amant, F; Massuger, LFAG; Pijnenborg, JMA

    L1CAM expression in endometrial carcinomas: an ENITEC collaboration study

    BRITISH JOURNAL OF CANCER 115 716-724. .

    [doi:10.1038/bjc.2016.235]

  • Guerra, E; Vidal, A; Gatius, S; Velasco, A; Piulats, JM; Ponce, J; Tallada, XG; Pardo, B; Martin, MG; Ortega, E; Guiu, XM

    Molecular classification of grade 3 endometrioid endometrial carcinomas: A retrospective study

    VIRCHOWS ARCHIV 469 20-20. .

  • Martinez-Garcia, E; Lesur, A; Devis, L; Campos, AR; Cabrera, S; van Oostrum, J; Matias-Guiu, X; Gil-Moreno, A; Reventos, J; Colas, E; Domon, B

    Development of a sequential workflow based on LC-PRM for the verification of endometrial cancer protein biomarkers in uterine aspirate samples

    Oncotarget 7 53102-53115. .

    [doi:10.18632/oncotarget.10632]

  • Jove, M; Gatius, S; Yeramian, A; Portero-Otin, M; Eritja, N; Santacana, M; Colas, E; Ruiz, M; Pamplona, R; Matias-Guiu, X

    Metabotyping human endometrioid endometrial adenocarcinoma reveals an implication of endocannabinoid metabolism

    Oncotarget 7 52364-52374. .

    [doi:10.18632/oncotarget.10564]

  • Hellner, K; Miranda, F; Fotso Chedom D; Herrero-Gonzalez, S; Hayden, DM; Tearle, R; Artibani, M; KaramiNejadRanjbar, M; Williams R; Gaitskell, K; Elorbany, S; Xu, RY; Laios, A; Buiga, P; Ahmed, K; Dhar, S; Zhang, RY; Campo, L; Myers, KA; Lozano, M; Ruiz-Miro, M; Gatius, S; Mota, A; Moreno-Bueno, G; Matias-Guiu, X; Benitez, J; Witty, L; McVean, G; Leedham, S; Tomlinson, I; Drmanac, R; Cazier, JB; Klein, R; Dunne, K; Bast, RC; Kennedy, SH; Hassan, B; Lise, S; Garcia, MJ; Peters, BA; Yau, C; Sauka-Spengler, T; Ahmed, AA

    Premalignant SOX2 overexpression in the fallopian tubes of ovarian cancer patients: Discovery and validation studies

    EBioMedicine 10 137-149. .

    [doi:10.1016/j.ebiom.2016.06.048]

  • Yeramian A; García V; Bergadà L; Domingo M; Santacana M; Valls J; Martinez-Alonso M; Carceller JA; Cussac AL; Dolcet X; Matias-Guiu X

    Bioluminescence Imaging to Monitor the Effects of the Hsp90 Inhibitor NVP-AUY922 on NF-kappa B Pathway in Endometrial Cancer

    MOLECULAR IMAGING AND BIOLOGY 18 545-556. .

    [doi:10.1007/s11307-015-0907-8]

  • Mirantes, C; Dosil, MA; Eritja, N; Felip, I; Gatius, S; Santacana, M; Matias-Guiu, X; Dolcet, X

    Effects of the multikinase inhibitors Sorafenib and Regorafenib in PTEN deficient neoplasias

    EUROPEAN JOURNAL OF CANCER 63 74-87. .

    [doi:10.1016/j.ejca.2016.04.019]

  • Campoy, I; Lanau, L; Altadill, T; Sequeiros, T; Cabrera, S; Cubo-Abert, M; Perez-Benavente, A; Garcia, A; Borros, S; Santamaria, A; Ponce, J; Matias-Guiu, X; Reventos, J; Gil-Moreno, A; Rigau, M; Colas, E

    Exosome-like vesicles in uterine aspirates: a comparison of ultracentrifugation-based isolation protocols

    Journal Of Translational Medicine 14 180-180. .

    [doi:10.1186/s12967-016-0935-4]

  • Santacana M; Coronado P; Matias-Guiu X; Romero I; Casado A; Gil-Moreno A; Dosil MA; Mota A; Moreno-Bueno G; Dolcet X; Llombart-Cussac A; Poveda A

    Biological Effects of Temsirolimus on the mTOR Pathway in Endometrial Carcinoma: A Pharmacodynamic Phase II Study.

    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER -. .

    [doi:10.1097/IGC.0000000000000715]

  • Schultheis, AM; Ng, CKY; De Filippo, MR; Piscuoglio, S; Macedo, GS; Gatius, S; Perez Mies B; Soslow, RA; Lim, RS; Viale, A; Huberman, KH; Palacios, JC; Reis-Filho, JS; Matias-Guiu, X; Weigelt, B

    Massively Parallel Sequencing-Based Clonality Analysis of Synchronous Endometrioid Endometrial and Ovarian Carcinomas

    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE 108 -. .

    [doi:10.1093/jnci/djv427]

  • Fuste, NP; Castelblanco, E; Felip, I; Santacana, M; Fernandez-Hernandez, R; Gatius, S; Pedraza, N; Pallares, J; Cemeli, T; Valls, J; Tarres, M; Ferrezuelo, F; Dolcet, X; Matias-Guiu, X; Gari, E

    Characterization of cytoplasmic cyclin D1 as a marker of invasiveness in cancer

    Oncotarget 7 26979-26991. .

    [doi:10.18632/oncotarget.8876]

Projects

  • Homologous recombination deficiency in high-grade endometrial cancers. Biomarkers and impact of intratumor heterogeneity.
  • EPH Receptor Signaling in Endometrial Cancer
  • Ajuts per a la contractació de personal investigador novell (FI)
  • Personalized Immunotherapy for Endometrial Cancer; Acronym: ExCITE (Endometrial Cancer Immunotherapy)
  • "Multi-Omics data for Cancer Research and the Development of New Diagnostics and Therapies"
  • EFFICACY: Nuevas estrategias para incrementar efectividad de los tratamientos con ABTL0812
  • Incorporación de nuevas areas temáticas y nuevos grupos al consorcio CIBER
  • Perfiles epigenéticos asociados a patrones de metastasis en cáncer de endometrio
  • CONTRACTES D'INCORPORACIO DE CIENTIFICS I TECNOLEGS: INCORPORACIO D'UNA DOCTORA PER A L'ACCIO ANTITUMORAL DELS CANNABINOIDES EN EL CARCINOMA D'ENDOMETRI
  • DISCOVERY, VALIDATION AND IMPLEMENTATION OF BIOMARKERS FOR PRECISION ONCOLOGY
  • Desarrollo de nuevas aproximaciones en el manejo individualizado de pacientes con cancer ginecológico (PREDICTGYN)
  • VALIDACION DE ANEXINA 2 COMO PREDICTOR DE RECIDIVA EN EL CANCER DE ENDOMETRIO. DISEÑO DE NUEVAS ESTRATEGIAS TERAPEUTICAS. ANXARECU